Humana Inc · Q3 2021 earnings

Briefing

Humana reported a strong third quarter, driven by the strength of its Medicare Advantage offerings and industry-leading customer experience. The company revised its full-year EPS guidance to reflect a net COVID headwind, while confirming the baseline for 2022 Adjusted EPS growth.

Humana Inc. reported strong third-quarter results, with GAAP earnings per diluted common share of $11.84 and adjusted earnings per share of $4.83. The company revised its full-year 2021 EPS guidance to approximately $23.67 on a GAAP basis, or approximately $20.50 on an Adjusted basis.

• Humana reported 3Q21 earnings per diluted common share of $11.84 on a GAAP basis, $4.83 on an Adjusted basis.
• The company revises FY 2021 EPS guidance to approximately $23.67 on a GAAP basis, or approximately $20.50 on an Adjusted basis.
• Humana achieved 97 percent, or 4.8 million of the company's Medicare Advantage members currently enrolled in 4-Star and above contracts for 2022.
• The company updates FY 2021 expected individual Medicare Advantage membership growth to 450,000 members, reflecting year-over-year growth of 11 percent.

Headline financials

Revenue & EPS history

Humana is revising its GAAP EPS guidance range for the year ending December 31, 2021 (FY 2021) to approximately $23.67 from the previous range of $24.97 to $25.47. Humana is also revising its FY 2021 Adjusted EPS guidance to approximately $20.50 from the previous guidance range of $21.25 to $21.75.